Litcius/Paper detail

Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Katharine H. D. Crawford, Adam S. Dingens, Rachel Eguia, Caitlin R. Wolf, Naomi Wilcox, Jennifer K. Logue, Kiel Shuey, Amanda M. Casto, Brooke Fiala, Samuel Wrenn, Deleah Pettie, Neil P. King, Alexander L. Greninger, Helen Y. Chu, Jesse D. Bloom

2020The Journal of Infectious Diseases282 citationsDOIOpen Access PDF

Abstract

Most individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develop neutralizing antibodies that target the viral spike protein. In this study, we quantified how levels of these antibodies change in the months after SARS-CoV-2 infection by examining longitudinal samples collected approximately 30-152 days after symptom onset from a prospective cohort of 32 recovered individuals with asymptomatic, mild, or moderate-severe disease. Neutralizing antibody titers declined an average of about 4-fold from 1 to 4 months after symptom onset. This decline in neutralizing antibody titers was accompanied by a decline in total antibodies capable of binding the viral spike protein or its receptor-binding domain. Importantly, our data are consistent with the expected early immune response to viral infection, where an initial peak in antibody levels is followed by a decline to a lower plateau. Additional studies of long-lived B cells and antibody titers over longer time frames are necessary to determine the durability of immunity to SARS-CoV-2.

Topics & Concepts

Neutralizing antibodyAntibodyAsymptomaticImmunologyVirologyAntibody titerMedicineTiterCoronavirusImmune systemRespiratory systemImmunityBiologyInternal medicineDiseaseCoronavirus disease 2019 (COVID-19)Infectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19
Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection | Litcius